Virtual Investor Event

Virtual Event | Now Available on Demand

Watch on Demand

 

Agenda

9:00 a.m. EDT

Welcome

Strategy Update

Andrin Oswald, CEO

Building the Leading Bio/Databank in Rare Diseases

Bettina Goerner, CDO

Superior Genomics Insights for Clinical Diagnostics

Max Schmid, CCO Diagnostics
Peter Bauer, CGO

Enabling and Accelerating Orphan Drug Development

Michael Motz, CCO Pharmaceuticals
Justin Bingham, SVP Business Development

Unlocking the Complexity of Rare Diseases with Multiomics

Volkmar Weckesser, CIO
Claudia Cozma, VP Biomarkers
Philip Lambert, CSO

Finance Priorities and Process Optimization

René Just, CFO

Q&A

11:00 a.m. EDT

Closing

Subscribe to receive regular corporate updates on CENTOGENE

Subscribe Now

 


Speakers

Andrin Oswald, M.D.

Andrin Oswald, M.D.

Chief Executive Officer

Andrin serves as CENTOGENE’s Chief Executive Officer – holding extensive experience in the healthcare sector.

Andrin was Director of Life Science Industry Engagement and Partnerships at the Bill & Melinda Gates Foundation, a role he held for four years in which he led the Foundation’s engagement with the industry and supported teams in developing and advancing its Global Health and Development priorities in R&D and delivery technologies.

Prior to his role at the Bill & Melinda Gates Foundation, he oversaw business integration at GlaxoSmithKline - working directly with the CEO to advise on business and integration strategy.

Before joining GlaxoSmithKline, he spent more than 10 years in a variety of leadership roles at Novartis, including serving as Assistant to the Chairman and CEO of Novartis International AG; Country President for Novartis South Korea; Head of Global Development Franchises and a member of the Executive Committee for Novartis Pharma; and ultimately, CEO/Division Head of Novartis Vaccines & Diagnostics and a member of the Novartis Executive Committee, based in Boston. Andrin began his career in 1999 with McKinsey & Company, where he worked in various roles managing relationships and supporting projects with leading pharmaceutical and diagnostics companies in Europe and the U.S.

Before joining CENTOGENE, Andrin served as the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, helping develop response and procurement strategies while advising the Swiss government on key decisions.

Throughout his career, he has also served on several boards, including the Novartis Foundation for Sustainable Development in Basel, Switzerland; the Global Health Innovation Technology Fund in Tokyo, Japan; and the Global Health Investment Corporation, where he was also a founding member.

Bettina Goerner

Bettina Goerner

Chief Data Officer

Bettina serves as CENTOGENE’s Chief Data Officer (CDO). Bringing 15 years of international industry experience and product-centricity, Bettina is responsible for ensuring that the management, governance, and commercialization of CENTOGENE’s data-based knowledge meets the highest quality standards.

Bettina previously served as Managing Director of Data Products & Services at Springer Nature – overseeing data and product development, as well as commercialization of five data products for R&D, including the AdisInsight databases for drug development. Bettina holds an undergraduate degree in Biochemistry from the University of Tübingen with practical research at Harvard Institutes of Medicine, as well as a master’s degree in Molecular Biology from the International Max Planck Research School. She started her career at McKinsey & Company and INSEAD Business School.

 

Bettina also holds board seats at Deepmatter Group Plc, a laboratory digitalization company focused on big data and experimental chemistry, as well as at Eagle Genomics Ltd., an innovator of data analysis software for life sciences and a Microsoft Genomics Partner.

Max Schmid, M.D.

Max Schmid, M.D.

Chief Commercial Officer - Diagnostics

Max serves as CENTOGENE’s Chief Commercial Officer Diagnostics. Bringing over two decades of Experience, Max has the overall responsibility of driving the company’s Diagnostic business strategy and growth. He joins CENTOGENE from Roche Diagnostics, where he most recently served as Global Head of Medical Affairs of its Sequencing Business Unit.

Within this role, he was responsible for developing and executing the medical strategy across different countries and disease areas, such as Oncology and Women’s Health. He came to Roche following the acquisition of Silicon Valley startup Ariosa Diagnostics Inc., where after a successful career in academic medicine, he helped build a leading global NIPT business.

Prior to his medical career, Max worked as a Management Consultant for McKinsey & Company – developing and implementing strategies and solutions to overcome complex challenges in the pharmaceutical and biotechnology industry.

Furthermore, he holds a medical degree from the University of Vienna and is board-certified with habilitation in Obstetrics and Gynecology and sub-specialty training in Maternal-Fetal Medicine, as well as certification in Clinical Genetics.

Peter Bauer, M.D.

Prof. Peter Bauer, M.D.

Chief Genomic Officer

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments. Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

Michael Motz, Ph.D.

Michael Motz, Ph.D.

Chief Commercial Officer - Pharmaceuticals

Michael serves as Chief Commercial Officer, Pharmaceuticals, overseeing the company's Pharma business strategy and growth. He is an entrepreneur and executive with over 25 years of industry experience and has held positions of increasing responsibility in both biotech and pharmaceutical companies during his career. He concluded several large transactions, licensing (in- and out-), and acquisitions with EU and U.S.-based life science companies, on both the buy side and the sell side. His experiences have also allowed him to gain expert knowledge in drug discovery and development for rare diseases, such as lysosomal storage diseases (LSDs) and certain rare bone disorders.

Michael holds a doctorate in Biochemistry from the Max Planck Institute for Evolutionary Anthropology, obtained under the supervision of renowned human geneticist Prof. Dr. h.c. Svante Pääbo. Before joining CENTOGENE, he was in leadership positions at several pharma and biotech companies, such as LION Bioscience AG, ALTANA Pharma, Sandoz, F. Hoffmann-La Roche AG, and Zealand Pharma. Most recently, Michael was Entrepreneur in Residence at BB Pureos Bioventures in Zurich, Switzerland.

Justin Bingham

Justin Bingham

SVP Business Development

Justin, as Senior Vice President of Business Development, leads a global team developing our pharmaceutical partnership strategy with the goal of maximizing value through accelerating and de-risking orphan drug programs for rare genetic diseases.

Prior to CENTOGENE, Justin was the Director of Business Development at Synthetic Genomics, Inc (SGI) and responsible for pharma and life science partnerships and collaborations. Justin also led the global marketing and sales activities for SGI-DNA, Inc., a wholly owned subsidiary of SGI and life sciences company developing synthetic biology tools and technologies with global applications. He draws from more than 10 years as a cell biologist working in preclinical drug discovery first with the Genomics Institute of the Novartis Research Foundation (GNF) and then the Exploratory Technologies Group within Pfizer Research and Development.

His broad experience as a scientist and in scaling life science and biotechnology companies to meet the demands of their partners provides a unique perspective and helps CENTOGENE to build value as a company.

Volkmar Weckesser, Ph.D.

Volkmar Weckesser, Ph.D.

Chief Information Officer

Volkmar serves as Chief Information Officer. Responsible for heading CENTOGENE's distributed and centralized business operations, he oversees the company's global development of the IT-based genetic software infrastructure and rare disease-centric Bio/Databank. Volkmar brings over 20 years of experience in IT, management of large transformation programs, and process optimization. He previously served as CIO of the Gothaer Insurance Enterprise and CEO of the incorporated Gothaer Systems GmbH, where he successfully implemented a new IT-strategy, realigned their IT-architecture, and restructured the project portfolio.

From 2009 to 2013, Volkmar was Director of IT at DekaBank – guiding the modernization of the IT systems and the establishment of new IT governance in close collaboration with all parties involved.

Prior to that, he served as Director of IT/Organization at the HSH Nordbank AG, where he focused on the planning and implementation of the enterprise-wide IT strategy. He also successfully executed the consolidation of the IT systems (post-merger IT integration) at the HSH Nordbank AG.

Volkmar started his career as a Management Consultant for the Mitchell Madison Group and Monitor Company.

He studied Technomathematics at the University of Karlsruhe and holds a doctorate in Mathematics.

Claudia Cozma, Ph.D.

Claudia Cozma, Ph.D.

VP Biomarker Development

Dr. Claudia Cozma is the Vice President of the Biomarker Development team at CENTOGENE and is responsible for leading the development, validation, and implementation of dried blood spot (DBS) based biochemical tests, especially including innovative biomarker identification and monitoring of rare diseases.

Additionally, she leads her team in the discovery of new biomarkers for rare diseases, including small metabolites, oligo-biopolymers, and proteins. Claudia oversees the team’s work with data analytics based on CENTOGENE’S developed machine learning algorithms and experimental confirmation of the biomarker candidates.

She finished her studies in Biochemistry and Ecology in Romania and holds a master’s in Biotechnology, followed by a doctorate in Natural Sciences in Analytical Chemistry from the University of Konstanz, Germany on the mass spectrometric structural studies of antibodies, namely epitope-paratope determination of polyclonal antibodies with application in Alzheimer Disease. She has experience in different mass spectrometric techniques, such as MALDI-ToF MS, MALDI-qToF MS, ESI-FT-ICR MS, MALDI-FT-ICR MS, ESI-ion trap MS, ESI-Orbitrap MS, ESI-TQ MS, ESI-IM-QToF, and ETD-QToF as well as hybrid techniques, such as affinity-MS, biosensor-MS, microchip-MS with application in proteomics, peptidomics, and metabolomics. She has worked at Centogene since 2014, providing outstanding know-how within the diagnostic world.

Philip Lambert, PhD

Philip Lambert

Chief Scientific Officer

With over two decades of scientific and operational experience in the drug discovery field, Philip has the overall responsibility of driving CENTOGENE’s scientific programs to align with the needs of pharmaceutical partners. Philip joins CENTOGENE from Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as Senior Vice President of Discovery and Labs as well as Chief Operating Officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences.

Prior to Life Biosciences, Philip served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms.

Rene Just

René Just

Chief Financial Officer

René Just serves as Chief Financial Officer. Within his role, he is responsible for the development and implementation of value creation strategies, as well as the planning and execution of financial strategies. René is a seasoned finance executive with over 20 years of industry experience. During his career, René has held positions of increasing responsibility in both listed and private equity owned companies, spanning a range of industries, including Pharma, IT, and Services. Throughout this time, René has gained extensive experience in building and leading efficient finance operations – supporting the development and implementation of value creation strategies, as well as the planning and execution of financing strategies.

René Just holds a Master of Economics from Aarhus University (Denmark). Before joining CENTOGENE, he was the Group CFO at Riemser Pharma Holding, previously owned by the private investment and private equity firm Ardian.

Press Release

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 22, 2021 (GLOBE NEWSWIRE)

Highlights strategic priorities to...

Event Presentation

Watch Our Virtual Investor Event on Demand

Watch on Demand

 

Virtual Investor Event - Listen on Demand

Event Program - Audio on Demand
Q&A Session - Audio on Demand

Contact Us

CENTOGENE Investor Relations

For more information, contact our IR team.

Contact IR

DISCLAIMER & SAFE HARBOR